DaVita Inc. (DVA)

NYQ – Real Time Price. Currency in USD

178.30

-0.04 (-0.02%)

Market open: Aug 12, 2026, 10:18 AM EDT

178.50

+0.16 (0.09%)

Previous after-hours: Aug 11, 2026, 7:58 PM EDT

06.08.2026

Is DaVita (DVA) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

05.08.2026

DaVita Stock Down in Pre-Market Despite Q2 Earnings Beat, Margins Down

DVA's second-quarter 2026 results show profit growth, but narrowing margins and a weaker commercial mix weigh on the performance.

05.08.2026

DVA Q2 Earnings Call Centers on Clinical-Led Volume Growth

DaVita's Q2 earnings call highlights mortality-led volume gains and broader middle molecule access, while management held 2026 guidance amid reimbursement pressure.

05.08.2026

DaVita Q2 Earnings Call Highlights

DaVita NYSE: DVA reported second-quarter results that management said were broadly in line with expectations, supported by accelerating treatment-volume growth and lower mortality among patients. The kidney-care company reaffirmed its full-year 2026 guidance, while outlining plans to expand access to newer dialysis technology designed to improve clearance of so-called middle molecules.

05.08.2026

DaVita Inc. (DVA) Q2 2026 Earnings Call Transcript

04.08.2026

DaVita flags lower revenue per treatment, reaffirms annual forecast

DaVita said on Tuesday revenue per treatment was lower in the second quarter, blaming declining enrollments for dialysis treatments as patients dropped ‌out of Obamacare plans following the end of pandemic-era subsidies.

04.08.2026

DaVita HealthCare (DVA) Q2 Earnings and Revenues Top Estimates

DaVita HealthCare (DVA) came out with quarterly earnings of $4.02 per share, beating the Zacks Consensus Estimate of $4.01 per share. This compares to earnings of $2.95 per share a year ago.

Videos

No Data

There is no data to display

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
DVA	TD Cowen	Buy	undefined >> $220	August 7th 2026

Press releases

04.08.2026

DaVita Inc. 2nd Quarter 2026 Results

DENVER, Aug. 4, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2026. "Thanks to the outstanding efforts of our teammates, we had another positive quarter for both patient outcomes and financial results," said Javier Rodriguez, CEO of DaVita Inc. "As we look to the rest of the year, we maintain our strategic focus on exciting new innovations in kidney dialysis to enhance the lives of our patients.

DaVita Inc. (DVA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

DaVita Inc. (DVA)

Is DaVita (DVA) a Great Value Stock Right Now?

DaVita Stock Down in Pre-Market Despite Q2 Earnings Beat, Margins Down